Can an enhanced medication information sheet improve drug responsiveness?

Not Applicable

• Conditions: Health literacy; Placebo response; Nocebo response; Mental Health - Studies of normal psychology, cognitive function and behaviour

• Registration Number: ACTRN12623000510640
• Lead Sponsor: niversity of Auckland

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-05-17
• Last Update Posted: 18 July 2023

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 82

Inclusion Criteria

Participants are eligible to take part in this study if they are 18 years or older, fluent in English, able to complete the questionnaires and willing to participate in the study.

Exclusion Criteria

Participants are not eligible to participate in the study if they are taking medications that interact with Metoprolol (e.g. anti-hypertensives, anti-arrhythmics) or have any medical conditions in which beta-blockers should not be used (e.g. asthma or diabetes).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome is the placebo response which is a composite primary outcome. The placebo response will be demonstrated by changes in blood pressure and heart rate, measured using the iHealth Wireless Blood Pressure Monitor. Using an inflatable cuff around the upper arm, this device measures a person’s systolic and diastolic blood pressure and heart rate. The placebo response will also be assessed by measuring participants' anxiety using The Short Form State-Trait Anxiety Inventory (STAI- 6) (Marteau & Bekker, 1992).[Post TSST (primary endpoint) and 24 hours post-intervention<br>];The nocebo response (side effect reporting measured with the Side Effect Attribution Scale - SEAS) (MacKrill, Webster, et al., 2021)[Post TSST (primary endpoint) and 24 hours post-intervention]